Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Liraglutide on Long-Term Weight Maintenance Following Weight Loss Induced by a 12-Week Low-Calorie Diet in Obese Subjects; A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Trial With a 12 Week Follow-up Period

Next Previous
Trial Profile

Effect of Liraglutide on Long-Term Weight Maintenance Following Weight Loss Induced by a 12-Week Low-Calorie Diet in Obese Subjects; A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Trial With a 12 Week Follow-up Period

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms SCALE; SCALE-Maintenance
  • Sponsors Novo Nordisk

Most Recent Events

  • 04 Sep 2020 Results determining whether video based online medical education for primary care physicians and diabetologists/endocrinologists can improve knowledge, competence and confidence regarding the collaborative management of patients with obesity, presented at the 2020 European and International Congress on Obesity
  • 20 May 2017 Results of a post-hoc analysis comparing outcomes in liraglutide 3.0 mg early responders vs. early non-responders who completed 56 weeks of treatment, presented at the 24th European Congress on Obesity.
  • 04 Apr 2016 Results (pooled analysis of this and other four trials, n = 5338) assessing neuropsychiatric Safety Profile presented at The 98th Annual Meeting of the Endocrine Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top